PHAT Relative Valuation
PHAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHAT is overvalued; if below, it's undervalued.
Historical Valuation
Phathom Pharmaceuticals Inc (PHAT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.10. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 14.59 USD , Phathom Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：14.59
Fair
Undervalued
-11.82
PE
1Y
3Y
5Y
Trailing
Forward
144.83
EV/EBITDA
Phathom Pharmaceuticals Inc. (PHAT) has a current EV/EBITDA of 144.83. The 5-year average EV/EBITDA is 0.67. The thresholds are as follows: Strongly Undervalued below -53.29, Undervalued between -53.29 and -26.31, Fairly Valued between 27.66 and -26.31, Overvalued between 27.66 and 54.64, and Strongly Overvalued above 54.64. The current Forward EV/EBITDA of 144.83 falls within the Strongly Overvalued range.
-86.65
EV/EBIT
Phathom Pharmaceuticals Inc. (PHAT) has a current EV/EBIT of -86.65. The 5-year average EV/EBIT is -7.19. The thresholds are as follows: Strongly Undervalued below -37.60, Undervalued between -37.60 and -22.39, Fairly Valued between 8.02 and -22.39, Overvalued between 8.02 and 23.23, and Strongly Overvalued above 23.23. The current Forward EV/EBIT of -86.65 falls within the Strongly Undervalued range.
3.75
PS
Phathom Pharmaceuticals Inc. (PHAT) has a current PS of 3.75. The 5-year average PS is 119.44. The thresholds are as follows: Strongly Undervalued below -326.28, Undervalued between -326.28 and -103.42, Fairly Valued between 342.30 and -103.42, Overvalued between 342.30 and 565.16, and Strongly Overvalued above 565.16. The current Forward PS of 3.75 falls within the Historic Trend Line -Fairly Valued range.
-22.02
P/OCF
Phathom Pharmaceuticals Inc. (PHAT) has a current P/OCF of -22.02. The 5-year average P/OCF is -4.44. The thresholds are as follows: Strongly Undervalued below -12.29, Undervalued between -12.29 and -8.37, Fairly Valued between -0.51 and -8.37, Overvalued between -0.51 and 3.42, and Strongly Overvalued above 3.42. The current Forward P/OCF of -22.02 falls within the Strongly Undervalued range.
-21.97
P/FCF
Phathom Pharmaceuticals Inc. (PHAT) has a current P/FCF of -21.97. The 5-year average P/FCF is -5.65. The thresholds are as follows: Strongly Undervalued below -18.13, Undervalued between -18.13 and -11.89, Fairly Valued between 0.58 and -11.89, Overvalued between 0.58 and 6.82, and Strongly Overvalued above 6.82. The current Forward P/FCF of -21.97 falls within the Strongly Undervalued range.
Phathom Pharmaceuticals Inc (PHAT) has a current Price-to-Book (P/B) ratio of -2.47. Compared to its 3-year average P/B ratio of -1.84 , the current P/B ratio is approximately 33.80% higher. Relative to its 5-year average P/B ratio of -2.05, the current P/B ratio is about 20.14% higher. Phathom Pharmaceuticals Inc (PHAT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -37.09%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -31.54% , the current FCF yield is about -100.00% lower.
-2.47
P/B
Median3y
-1.84
Median5y
-2.05
-22.06
FCF Yield
Median3y
-37.09
Median5y
-31.54
Competitors Valuation Multiple
The average P/S ratio for PHAT's competitors is 0.41, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 202.74%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PHAT increased by 81.03% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 16.35M to 49.50M.
The secondary factor is the P/E Change, contributed -33.28%to the performance.
Overall, the performance of PHAT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Phathom Pharmaceuticals Inc (PHAT) currently overvalued or undervalued?
What is Phathom Pharmaceuticals Inc (PHAT) fair value?
How does PHAT's valuation metrics compare to the industry average?
What is the current P/B ratio for Phathom Pharmaceuticals Inc (PHAT) as of Dec 05 2025?
What is the current FCF Yield for Phathom Pharmaceuticals Inc (PHAT) as of Dec 05 2025?
What is the current Forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT) as of Dec 05 2025?